Free tool
FAERS Monitor: Ctexli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219488 or its brand name (Ctexli, Chenodiol). Reports on generic versions are filed under their own applications.
Reports
32
Serious
17
53% of reports
Hospitalization
11
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dehydration5
- off label use5
- adenovirus infection4
- anaphylactic shock4
- drug ineffective4
- ear infection4
- gastroenteritis viral4
- herpes zoster disseminated4
- human bocavirus infection4
- lymphopenia4
- multiple organ dysfunction syndrome4
- optic neuritis4
- renal failure4
- respiratory failure4
- retinitis4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| human bocavirus infectionSignal | 4 | 14225.8 | 5624.3 | 42,638 |
| herpes zoster disseminatedSignal | 4 | 3293.8 | 1313.5 | 10,031 |
| retinitisSignal | 4 | 1525.7 | 609.3 | 4,655 |
| adenovirus infectionSignal | 4 | 907.8 | 362.7 | 2,770 |
| optic neuritisSignal | 4 | 289.5 | 115.7 | 880 |
| lymphopeniaSignal | 4 | 186.0 | 74.3 | 563 |
| gastroenteritis viralSignal | 4 | 145.7 | 58.2 | 439 |
| anaphylactic shockSignal | 4 | 102.0 | 40.8 | 306 |
| ear infectionSignal | 4 | 98.8 | 39.5 | 296 |
| multiple organ dysfunction syndromeSignal | 4 | 92.8 | 37.1 | 278 |
| respiratory failureSignal | 4 | 36.1 | 14.4 | 104 |
| dehydrationSignal | 5 | 24.6 | 11.0 | 92 |
| renal failureSignal | 4 | 19.8 | 7.9 | 54 |
| off label useSignal | 5 | 3.8 | 1.7 | 8 |
| drug ineffective | 4 | 2.0 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.